TauRx Therapeutics Ltd (sponsor), 2013-01: Registry entry for the phase 3 TRx-237-015 trial (891 participants, mild to moderate Alzheimer's disease) comparing TRx0237 150 mg/day and 250 mg/day with an active 'placebo' containing 4 mg TRx0237 twice daily; completed with no results posted on the registry.
Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding
record field (interventions)
TauRx Therapeutics Ltd (sponsor), 2013-01: Registry entry for the phase 3 TRx-237-015 trial (891 participants, mild to moderate Alzheimer's disease) comparing TRx0237 150 mg/day and 250 mg/day with an active 'placebo' containing 4 mg TRx0237 twice daily; completed with no results posted on the registry. Record field, not prose; confidence MEDIUM. Study type: interventional, randomised, double-blind, placebo-controlled, phase 3. Enrollment 891 actual. Countries: multinational. Doses 150 mg/day and 250 mg/day; control 8 mg/day total TRx0237 (described as active placebo/colourant). Primary outcomes ADAS-cog11 and ADCS-ADL23 at 65 weeks. Status COMPLETED 2015-11; results not posted on ClinicalTrials.gov (published in Lancet 2016 instead) – 'registered, no results'. Sponsor and funder: TauRx Therapeutics Ltd. Conflicts: sponsor-run. Also filed as MTE-33, MTP-27, MTC-092 (claims C3, C4, C8, F1). Study type: regulatory record.
